Cargando…

Remdesivir: Rebound effect in the form of SARS-CoV-2 infection following off label use: 2 case reports

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913189/ http://dx.doi.org/10.1007/s40278-022-11557-8

Ejemplares similares

Antibacterials/convalescent-anti-SARS-CoV-2-plasma/remdesivir: Treatment failure and off-label use: case report
Publicado: (2021)

Convalescent-anti-SARS-CoV-2-plasma/dexamethasone/remdesivir: Off-label use and lack of efficacy: case report
Publicado: (2021)

Convalescent-anti-SARS-CoV-2-plasma/remdesivir/rituximab: COVID-19 infection, and lack of efficacy following off-label use: 20 case reports
Publicado: (2022)

SARS-CoV-2 rebound with and without antivirals
por: Petrosillo, Nicola
Publicado: (2023)

Remdesivir/methylprednisolone/convalescent-anti-SARS-CoV-2-plasma: Elevated aminotransferase levels and off-label use: case report
Publicado: (2021)

Rebound of SARS-CoV-2 Infection after Nirmatrelvir–Ritonavir Treatment
por: Charness, Michael E., et al.
Publicado: (2022)

Arguments in favour of remdesivir for treating SARS-CoV-2 infections
por: Ko, Wen-Chien, et al.
Publicado: (2020)

Therapeutic Efficacy and Outcomes of Remdesivir versus Remdesivir with Tocilizumab in Severe SARS-CoV-2 Infection
por: Vulturar, Damiana-Maria, et al.
Publicado: (2022)

An explanation for SARS-CoV-2 rebound after Paxlovid treatment
por: Perelson, Alan S., et al.
Publicado: (2023)

SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy
por: Edelstein, Gregory E., et al.
Publicado: (2023)

Quantifying the effect of remdesivir in rhesus macaques infected with SARS-CoV-2
por: Dobrovolny, Hana M.
Publicado: (2020)

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
por: Williamson, Brandi N., et al.
Publicado: (2020)

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
por: Williamson, Brandi N., et al.
Publicado: (2020)

Early experience with remdesivir in SARS-CoV-2 pneumonia
por: Durante-Mangoni, Emanuele, et al.
Publicado: (2020)

Contre Sars-CoV-2, brequinar ou remdesivir ?
por: Manus, Jean-Marie
Publicado: (2021)

Remdesivir therapy associated with Bradycardia in SARS‐CoV2
por: Kumar, Sabina, et al.
Publicado: (2021)

Mechanism of SARS-CoV-2 polymerase stalling by remdesivir
por: Kokic, Goran, et al.
Publicado: (2021)

Enhanced Remdesivir Analogues to Target SARS-CoV-2
por: Majima, Ryuichi, et al.
Publicado: (2023)

Convalescent-anti-sars-cov-2-plasma/dexamethasone/remdesivir: Lack of efficacy and off label use: case report
Publicado: (2022)

Convalescent-anti-SARS-CoV-2-plasma/immunosuppressants: SARS-CoV-2 infection, its re-infection and off label use: case report
Publicado: (2021)

Mathematical model of SARS-CoV-2 immunity predicts Paxlovid rebound
por: Ranard, Benjamin L., et al.
Publicado: (2023)

Human soluble ACE2 improves the effect of remdesivir in SARS‐CoV‐2 infection
por: Monteil, Vanessa, et al.
Publicado: (2020)

Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir
por: Negru, Paul Andrei, et al.
Publicado: (2022)

Use of Antivirals in SARS-CoV-2 Infection. Critical Review of the Role of Remdesivir
por: Moreno, Santiago, et al.
Publicado: (2022)

Use of remdesivir in kidney transplant recipients with SARS-CoV-2 Omicron infection
por: Cacho, Judit, et al.
Publicado: (2022)

Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection
por: Heyer, Andreas, et al.
Publicado: (2022)

Methylprednisolone: Worsening of SARS-CoV-2 infection during off-label treatment: case report
Publicado: (2020)

Remdesivir in kidney transplant patients with SARS-CoV-2 pneumonia()
por: Cacho, Judit, et al.
Publicado: (2022)

Remdesivir: Renal dysfunction and liver dysfunction following off-label use: 2 case reports
Publicado: (2022)

Convalescent-anti-sars-cov-2-plasma/remdesivir: Sinus bradycardia, elevated ALT and off-label use: case report
Publicado: (2021)

Multiple drugs: SARS-CoV-2 pneumonia and off-label use
Publicado: (2021)

Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice
por: Pruijssers, Andrea J., et al.
Publicado: (2020)

Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection
por: Ye, Zi-Wei, et al.
Publicado: (2021)

Immune-globulin/methylprednisolone/tocilizumab: Lack of response following off-label use in SARS-CoV-2 infection: case report
Publicado: (2021)

Anakinra/convalescent-anti-SARS-CoV-2-plasma/prednisolone: Aggravation of SARS-CoV-2 hepatitis, SARS-CoV-2 viraemia and off-label use: case report
Publicado: (2021)

Dexamethasone/prednisone/rituximab: Prolonged SARS-CoV-2 infection and off-label use: case report
Publicado: (2022)

Azithromycin/ceftriaxone/remdesivir: Bradycardia and lack of efficacy following off-label use: 2 case reports
Publicado: (2022)

Convalescent-anti-SARS-CoV-2-plasma: Lack of efficacy following off-label use: case report
Publicado: (2021)

Convalescent-anti-SARS-CoV-2-plasma: Lack of efficacy following off-label use: case report
Publicado: (2022)

Remdesivir/tocilizumab: Drug ineffective and off-label use: 2 case reports
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6r58ftmnc67cukskgvp1r015de